RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancer

Background: Abnormal regulation of genes has been closely related to gastric cancer. The characterization cancer necessitated the development new therapeutics as well identification prognostic markers predict response novel drugs. In our study, we used RNA sequencing analyses show that on tissues markers. We specifically chose study RNF43 because it inhibits cancer-related Wnt/β-catenin signaling by interacting with Wnt receptors. PWWP2B was chosen is a gene which downregulated in Methods: Utilizing analysis, evaluated mRNA expression profile patients. Also, HAP1 cells human near-haploid cell line derived from male chronic myelogenous leukemia KBM-7. These one copy each gene, ensuring edited allele will not be masked additional alleles. investigated screening 1,449 FDA-approved drugs HAP1, KO and cells. data reveals were down-regulated recurrence Next, anti-cancer effects selected MKN45 xenograft model. Results: Among these drugs, three (docetaxel trihydrate, pelitinib uprosertib) showed strong inhibitory model, tumor volumes significantly reduced docetaxel uprosertib or pelitinib-treated group. Our demonstrated are biomarker Conclusions: findings suggest could therapeutic agents for prevention treatment decrease expression.